PI: Kevin Finkel, MD

This study is about evaluating the impact of conflicting financial relationships between clinical study investigators and the manufacturer of Liposomal bupivacaine LB (Pacira Pharmaceuticals, Inc.; parent company, Pacira Biosciences, Inc.) on the reporting of positive clinical outcomes. The aim of this systematic review is to evaluate the prevalence and nature of financial conflicts of interest (FCOIs) between clinical study investigators and the manufacturer of LB. We also evaluated the relationship between FCOIs and the reporting of positive clinical outcome data favoring LB. Phase 1 of this study was completed, we will soon be starting on phase 2 where we will be evaluating the impact of conflicting financial relationships regarding other considerably expensive pain medications.